The 2025 Leapfrog Safety Grades are in — and HonorHealth is once again at the top of the class! HonorHealth has the highest "GPA" among the multi-hospital systems in the Valley, showing a strong and consistent commitment to high quality care, especially patient safety. This comes even as we acquired three new hospitals into the HonorHealth family. 👏 Leapfrog Hospital Safety Grades are assigned to nearly 3,000 general acute-care hospitals across the nation, twice annually. It's considered the gold standard measure of patient safety. Our grades reflect the culture of excellence we have at HonorHealth; an amazing place to heal and to work. (fb)

HonorHealth Research Institute has become the first of 50 global sites to treat a patient in a groundbreaking melanoma clinical study. This trial evaluates a novel T-cell therapy targeting PRAME, a protein commonly overexpressed in melanoma tumors. The therapy involves engineering a patient's own T cells to recognize and attack PRAME-expressing cancer cells, offering new hope for patients with advanced melanoma. Dr. Justin Moser, a leading clinician-investigator at HonorHealth and associate research professor at Arizona State University's new School of Medicine and Advanced Medical Engineering, emphasized the transformative potential this therapy holds for patients who face limited treatment options and poor prognoses. Learn more about this innovative approach: https://bit.ly/3RGLf5B (fb)